Phenelzine

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Phenelzine
    1. Pharmacist Assessment Report
    2. Phenelzine: Known uses and market status in Australia
    3. Summary
    4. Quick overview
    5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. Australia Market Information
    7. Safety Considerations
    8. Disclaimer

Pharmacist Assessment Report

Phenelzine: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Phenelzine, so there is currently no new predicted indication. The drug’s recorded uses are listed below; they are the drug’s own recorded uses, not model candidates.

Quick overview

Item Content
New predicted indications None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug 3
Evidence level Not applicable
Australia Market Status Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication Source
none none
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
anxiety disorder
dysthymic disorder
neurotic disorder

Australia Market Information

Licence Product Dosage form Status
13148B Nardil (Canada) Tablet 15 mg (as sulfate) s19A Valid

Safety Considerations

  • Contraindications flagged in the knowledge graph (not label text): hypertension and other cardiovascular disease (including coronary artery disease, heart conduction disease and sudden cardiac arrest), orthostatic hypotension, phaeochromocytoma and paraganglioma, hyperthyroidism, epilepsy, liver disease, kidney disease, diabetes and diabetic ketoacidosis, bipolar disorder, and substance abuse/dependence. These should be checked against the Product Information.
  • Drug interactions: 100 interactions were identified. Examples rated Major include bupropion, morphine, lorcaserin, phentermine, diethylpropion, isometheptene, dolasetron and palonosetron. Examples rated Moderate include epinephrine, glimepiride, repaglinide, chlorpropamide, insulin aspart and dronabinol. Examples rated Minor include atropine, hyoscyamine and dicyclomine. Serotonin syndrome has been reported with SSRI co-administration (for example sertraline).
  • Other reported effects (literature): reduced plasma vitamin B6, weight gain, orgasmic inhibition, and a rare case of leukopenia.

Please also refer to the TGA-approved Product Information (PI) for full warnings, contraindications and dietary restrictions.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



This site uses Just the Docs, a documentation theme for Jekyll.